CADTH has received notice of pending submissions from BMS for asunaprevir and daclatasvir dihydrochloride (Daklinza) for patients with hepatitis C virus infection.  For information about the patient input process or for additional instructions, please see the patient onput page of the CADTH website. Note that only patient groups may submit input.

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input-form/398